Research, development, innovation and quality are concepts inherent to BIOLAB and have directly contributed to turn the company into a referent in the Brazilian pharmaceutical industry. BIOLAB, which holds private, one hundred percent national capital, is leader in cardiovascular prescription medicines and is among the best ten companies in the ranking of medicines sold under medical prescription. It is positioned as one of the most solid and highly regarded companies in the Brazilian pharmaceutical sector.
From its foundation, in 1997, BIOLAB carries in its DNA the vocation for research and believes this is the way towards the development of new technologies and products with added technological value. The innovation process, supported by a strong internal structure, comprises also important partnership agreements signed with research centers, universities, suppliers, public organisms and other pharmaceutical industries. This innovative profile is reflected on the investments carried out: seven percent of the yearly sales are allocated for Research, Development and Innovation, the highest percentage of the sector in the country. The company has an exclusive production area for nanotechnology and is investing in the construction of a new center for advanced research. The constant search for innovation generated about 100 ongoing research projects and reached, in eight years, valuable increase in the number of filed patents.
Together with its innovative profile, BIOLAB excellence in financial, administrative and industrial management is increasingly recognized in the market. In 2011, the company achieved the 1st place in the Pharmaceutical and Cosmetic general category. The yearbook is published
by Valor Econômico - one of the most important Brazilian newspapers.
BIOLAB has two thousand employees and one of the largest sales-force in Brazil, visiting more than two hundred twenty thousand doctors per month.
BIOLAB develops prescription medication for specialties such as cardiology, gynecology, dermatology, orthopedics, rheumatology, general clinic, pediatrics, gastroenterology, endocrinology and geriatrics. Also acts strongly in the segment of dermo-cosmetics, developing products with
innovative technology and resources from the Brazilian biodiversity that are appropriate for the diverse climates in the country and the Brazilian skin types.
The investment in people, innovation, administrative and operational excellence leads BIOLAB to daily.
